The latest price target for Eupraxia Pharmaceuticals (NASDAQ:EPRX) was reported by Rodman & Renshaw on November 14, 2024. The analyst firm set a price target for $9.00 expecting EPRX to rise to within 12 months (a possible 150.00% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Eupraxia Pharmaceuticals (NASDAQ:EPRX) was provided by Rodman & Renshaw, and Eupraxia Pharmaceuticals initiated their buy rating.

There is no last upgrade for Eupraxia Pharmaceuticals

There is no last downgrade for Eupraxia Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Eupraxia Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Eupraxia Pharmaceuticals was filed on November 14, 2024 so you should expect the next rating to be made available sometime around November 14, 2025.

While ratings are subjective and will change, the latest Eupraxia Pharmaceuticals (EPRX) rating was a initiated with a price target of $0.00 to $9.00. The current price Eupraxia Pharmaceuticals (EPRX) is trading at is $3.60, which is within the analyst’s predicted range.